Genetic Diversity Among Botulinum Neurotoxin Producing Clostridial Strains by Hill, K K et al.
UCRL-JRNL-222662
Genetic Diversity Among
Botulinum Neurotoxin Producing
Clostridial Strains
K. K. Hill, T. J. Smith, C. H. Helma, L. O. Ticknor, B. T.
Foley, R. T. Svennson, J. L. Brown, E. A. Johnson, L.
A. Smith, R. T. Okinaka, P. J. Jackson, J. D. Marks
July 7, 2006
Journal of Bacteriology
This document was prepared as an account of work sponsored by an agency of the United 
States Government. Neither the United States Government nor the University of California nor 
any of their employees, makes any warranty, express or implied, or assumes any legal liability 
or responsibility for the accuracy, completeness, or usefulness of any information, apparatus, 
product, or process disclosed, or represents that its use would not infringe privately owned 
rights. Reference herein to any specific commercial product, process, or service by trade 
name, trademark, manufacturer, or otherwise, does not necessarily constitute or imply its 
endorsement, recommendation, or favoring by the United States Government or the University 
of California. The views and opinions of authors expressed herein do not necessarily state or 
reflect those of the United States Government or the University of California, and shall not be 
used for advertising or product endorsement purposes. 
 
Updated October 14, 2003 
page 1 
 
 
p-[00000000 
Genetic Diversity Among Botulinum Neurotoxin Producing Clostridial  Strains  
K.K. Hill1*, T.J. Smith2, C.H. Helma1, L.O. Ticknor3, B.T. Foley4, R.T. Svensson1, J.L. Brown2 
E.A. Johnson5, L.A. Smith2, R.T. Okinaka1, P.J. Jackson6 and J.D. Marks7 
 
1Bioscience, 3Decision Applications and 4Theoretical Divisions, Los Alamos National 
Laboratory,  Los Alamos, NM 87545; 
2Integrated Toxicology Division, United States Army Medical Institute of Infectious Diseases 
(USAMRIID), Fort Detrick, MD 21702 
5Department of Food Microbiology and Toxicology, Food Research Institute (FRI), University 
of Wisconsin, Madison, WI 53706 
6Defense Biology Division, Lawrence Livermore National Laboratory,  Livermore,  CA 94551 
 7Department of Anesthesia and Pharmaceutical Chemistry, University of California, San 
Francisco, San Francisco,  Rm 3C-38, San Francisco General Hospital, 1001 Potrero Ave, San 
Francisco, CA 94110 
 
*Corresponding author: Bioscience Division, MS M888, Los Alamos National Laboratory, Los 
Alamos, NM 87545, Phone: (505) 667-1309, FAX (505) 665-3024, email:  khill@lanl.gov 
 
This work was partially supported by DoD contract DAMD17-03-C-0076 and by NIAID 
cooperative agreement U01 AI056493 
page 2 
 
Keywords: Clostridium botulinum neurotoxin, sequence diversity, BoNT, AFLP, 16s rRNA 
Running title: Genetic diversity of Clostridium botulinum strains 
 
Abbreviations: AFLP: amplified fragment length polymorphism, BoNT: botulinum neurotoxin, 
rRNA: ribosomal ribonucleic acid, SNP: single nucleotide polymorphism, PCR: polymerase 
chain reaction 
 
page 3 
 
Abstract 
 Clostridium botulinum is a taxonomic designation for many diverse anaerobic spore-
forming rod-shaped bacteria which have the common property of producing botulinum 
neurotoxins (BoNTs).  The BoNTs are exoneurotoxins that can cause severe paralysis and even 
death in humans and various other animal species. A collection of 174 C. botulinum strains were 
examined by amplified fragment length polymorphism (AFLP) analysis and by sequencing of the 
16S  rRNA gene and BoNT genes to examine genetic diversity within this species.  This 
collection contained representatives of each of the seven different serotypes of botulinum 
neurotoxins  (BoNT A-G).  Analysis of the16S rRNA sequences confirmed earlier reports of at 
least four distinct genomic backgrounds (Groups I-IV) each of which has independently acquired 
one or more BoNT serotypes through horizontal gene transfer.   AFLP analysis provided higher 
resolution, and can be used to further subdivide the four groups into sub-groups.  Sequencing of 
the BoNT genes from serotypes A, B and E in multiple strains confirmed significant sequence 
variation within each serotype.  Four distinct lineages within each of the BoNT A and B 
serotypes, and five distinct lineages of serotype E strains were identified.  The nucleotide 
sequences of the seven serotypes of  BoNT were compared and show varying degrees of inter-
relatedness and recombination as has been previously noted for the NTNH gene which is linked 
to BoNT.  These analyses contribute to the understanding of the evolution and phylogeny within 
this species and assist in the development of improved diagnostics and therapeutics for treatment 
of botulism. 
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Introduction 
Clostridium botulinum is a taxonomic collection of several distinct species of anaerobic 
gram positive spore-forming bacteria which produce the most poisonous substance known, 
botulinum neurotoxin (BoNT) (7).  These organisms, along with related neurotoxin-producing 
species which for a variety of reasons were not included under the C. botulinum taxon, pose 
global health problems that affect both infants and adult humans, and can also affect wildlife, 
waterfowl  and domestic animals. They cause intoxication through ingestion of the neurotoxin in 
contaminated foods and also in some cases toxicoinfections occur after contact with bacteria or 
bacterial spores (8, 18). These pathogens are ubiquitous and can be found in soils and sediments 
in both fresh water and marine environments (44). 
 
BoNTs are classified by the Centers for Disease Control (CDC) as one of the six highest-
risk threat agents for bioterrorism (the “Category A agents”), due to their extreme potency and 
lethality, ease of production and transport, and need for prolonged intensive care (1).  Both Iraq 
and the former Soviet Union produced BoNT for use as weapons (5, 9) and the Japanese cult 
Aum Shinrikyo attempted to use BoNT for bioterrorism (1).  Since the terrorist events of 
September 11, 2001 and the subsequent intentional terror release of anthrax spores, development 
of environmental toxin sensors, diagnostic tests for botulism, and specific countermeasures for 
prevention and treatment of intoxication have become a high priority.  The first step in such 
research is to define the spectrum of diversity of BoNT producing clostridial species and the 
toxins they produce. 
 
C. botulinum strains are usually described as belonging within one of four different 
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Groups (I, II, III, and IV) based on physiologic characteristics (19).   The toxins produced by 
them are categorized into seven serologically distinct groups (A through G), based on 
recognition by polyclonal serum (18).  The BoNT is encoded by an approximately 3.8 kb gene, 
preceded by a non-toxic-non-hemagglutinin (NTNH) gene and several other genes encoding 
toxin-associated proteins (HA-17, HA-33, HA-70, p21 and/or p47) (3, 7, 12, 13, 34).  The BoNT 
gene for serotype A, B, E and F strains can be found within the bacterial chromosome.  Serotype 
C and D strains produce toxin from a phage genome, and serotype G strains contain a plasmid 
with the toxin operon (34).  Strains producing inter-serotype recombinant toxins have been 
noted, primarily the C/D and D/C phage-encoded serotypes (32, 33).  Additionally, several 
strains produce multiple toxins.  Bivalent strains of C. botulinum, each producing two toxins of 
serotypes Ab, Ba, Af, and Bf have been noted (16, 36).  
 
The genomic background housing these BoNT genes within C. botulinum has been 
identified as very diverse, and in addition other species have been known to harbor BoNT genes, 
such as C. butyricum (BoNT E) (2, 31), C.baratii (BoNT F) (17) and C. argentinense (BoNT G) 
(41).  Previous16S rRNA analysis of many different Clostridium species has shown the C. 
botulinum form four distinct clusters, with each cluster representing one of the four different 
physiological Groups (I-IV) (7, 23).  Previous AFLP analysis of 70 C. botulinum BoNT/A, B, E 
and F strains showed that this technique could also successfully differentiate strains into the 
distinct Group 1 and Group II clusters (26).  Like the 16S rRNA analysis, the AFLP results show 
that the Group I cluster included BoNT/A, B and F proteolytic strains while Group II contained 
BoNT/E and nonproteolytic B and F strains (26).  Thus, the phylogeny of these species based on 
molecular analyses has supported the current taxonomy which has been based on the physiologic 
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attributes of the species and the toxins produced.  Such analyses have contributed to the 
understanding of the diversity of the genomic backgrounds that house the very different BoNT 
genes. 
 
Recently it has become appreciated that there is significant sequence diversity (subtypes) 
within the BoNT genes and toxins of at least six of the seven serotypes (37).  The relationship 
between toxin gene diversity and clostridial genomic diversity is unknown.  Such subtypes can 
differ by 2.6% to 31.6% percent at the amino acid level, and these differences can affect the 
binding and neutralization by monoclonal and polyclonal antibodies (14, 29, 37).  Since analysis 
of only 48 published full length toxin gene sequences revealed the presence of 18 different 
subtypes, it is likely that additional subtypes might exist (37).  Defining the extent of such toxin 
diversity would be a first step in the development of detection systems and countermeasures for 
prevention and treatment of botulism. In addition, analysis of a large population of strains can be 
used to better understand the evolutionary relationship between the toxin moieties and the 
genomic backgrounds that house these toxins. 
 
In order to understand the extent of toxin gene diversity and the relationship between 
genomic diversity between C. botulinum serotypes and subtypes and other toxin-producing 
species of Clostridium, 174 toxin-producing strains were analyzed from a collection that 
included representatives of all neurotoxin serotypes (BoNT A-G).  Several methods were used to 
examine the strains including sequencing of the 16S rRNA gene, analysis of the genome by 
amplified fragment length polymorphism (AFLP), and sequencing of BoNT/A, B and E 
neurotoxin genes.  Nucleotide sequences of the 16S rRNA and BoNT gene from these and other 
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previously sequenced Clostridium strains were analyzed by phylogenetic and recombination 
detection methods. The phylogenetic relationships among these strains based on all of these 
methods are presented, as well as the extent of toxin gene diversity and the relationship between 
toxin types, subtypes, and genomic differences. 
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Materials and Methods 
Strains  
Strains of BoNT producing Clostridia were obtained from USAMRIID, Frederick, MD, 
and the Department of Food Microbiology and Toxicology, University of Wisconsin, Madison 
WI.  Many of these strains were part of the Virginia Polytechnic Institute (VPI) Anaerobe 
Laboratory collection.  Strains were serotyped using antibody capture ELISA with serotype-
specific monoclonal antibodies.  In some cases, serotypes were confirmed using mouse 
neutralization (20).  Silent (not expressed) BoNT/B genes were detected using real time PCR (6).          
 
DNA isolation and purification 
Individual bacterial colonies of each of the C. botulinum strains were removed from 
anaerobic CDC blood agar plates and used to inoculate 100 ml TPGY broth (Difco, Becton 
Dickinson and Co., Franklin Lakes, NJ).  The broth cultures were incubated anaerobically for 48 
hours at 35°C then harvested by low speed centrifugation.  The pellets were resuspended in 
8.5ml TE buffer (10mM Tris, 1mM EDTA, pH 8.0) then quickly frozen in a dry ice/ethanol bath 
and stored at –70°C until further processing.  Upon removal, the resuspended pellets underwent 
three successive freeze/thaw cycles of freezing in a dry ice/ethanol bath followed by melting at 
65°C.  Sodium dodecylsulfate (SDS) (450 ul) and 45ul of Proteinase K (10mg/ml) were added, 
mixed, and incubated at 42°C for 1 hour.  After incubation, 1.5 ml of 5M NaCl solution and 
1.4ml of a 10% CTAB (cetyl trimethyl ammonium bromide) solution were added, mixed 
thoroughly and incubated at 65°C for 10 minutes.  Following this incubation, three organic 
extractions of the mixture were performed.  The initial extraction involved the addition of an 
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equal volume of a chloroform/isoamyl alcohol (24:1) with incubation while rocking for 10 
minutes. Following low speed centrifugation the aqueous phase was removed and extracted 
again by adding an equal volume of phenol/chloroform/isoamyl alcohol (25:24:1). For the final 
extraction an equal volume of chloroform/isoamyl alcohol (24:1) was added. After low speed 
centrifugation, the nucleic acids in the upper phase were precipitated with isopropanol.  After 
centrifugation the pellet was washed with a 70% ethanol solution then resuspended in 2.0ml TE 
buffer. The DNA preparation was quantified with a spectrophotometer, diluted to 25 ug/ml, and 
analyzed on an agarose gel to determine quality.   
 
Amplified Fragment Length Polymorphism (AFLP) analysis of DNA samples 
Each sample consisted of 100 ng of DNA that was digested with the restriction 
endonucleases EcoRI and MseI and the resulting fragments were ligated to double-stranded 
adapters. The digested and ligated DNA was then amplified by PCR using EcoRI and MseI 
+0/+0 primers (5’-GTAGACTGCGTACCAATTC-3’ and 5’-GACGATGAGTCCTGAGTAA-3’ 
respectively).  Five µl of each product was used as template in subsequent selective 
amplifications using the +1/ +1 primer combination of 6-carboxyfluorescein-labeled EcoRI-T 
(5’-GTAGACTGCGTACCAATTCT-3’) and MseI-T (5’-GACGATGAGTCCTGAGTAAT-3’). 
Selective amplifications were performed in 20 µl reaction mixtures. The resulting products (0.5 
to 1.0 µl) were mixed with a solution containing DNA size standards,Genescan-500 (Applied 
Biosystems Inc., Foster City, CA) labeled with N,N,N,N-tetramethyl-6-carboxyrhodamine.  
Following a 5 minute heat denaturation at 95°C, the reactions were loaded on an ABI 3100 
automated fluorescent sequencer. Each set of AFLP reactions also contained a control DNA as a 
template. Inclusion of such a reaction in each run and analysis set allowed a comparison of 
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results from earlier archived analysis sets run at different times. Genescan analysis software 
(Applied Biosystems, Inc. Foster City, CA) was used to determine the lengths of the sample 
fragments by comparison to the DNA fragment length size standards included with each sample.   
To minimize capillary gel electrophoresis artifacts, each labeling reaction product was run in 
triplicate.  Samples were loaded into a 96 well plate in a random order. 
 
AFLP data analysis was performed as described by Ticknor et al. (42). Sample fragments 
between 100 and 500 bp and with fluorescence above 50 arbitrary units in all three runs on the 
ABI sequencer were used in the analysis. Similarities among samples were determined using 
three separate methods to allow comparisons between methods. First, the Jaccard coefficient was 
used which compares the presence and absence of fragments of a given length.  Second, 
Euclidean distance with the relative abundance values was used, so that both presence and 
abundance are compared.  Third, a Manhattan distance was used, which is similar to Euclidean 
distances except that the absolute value instead of the squared value is reported. The 40 tallest 
peaks for each sample fingerprint were used to calculate the distance coefficients among 
samples. Dendrograms were produced using each of the three similarity matrices using the 
unweighted  pair-group average (UPGMA) agglomerative hierarchical clustering method (25). 
All statistical data manipulations were done using codes developed in S-Plus (Data Analysis 
Products Division, MathSoft, Seattle, WA). The dendrograms using the Euclidian and Manhattan 
distances, which include relative fragment abundance values, were compared to the Jaccard 
distance dendrogram and there were no differences in the groupings.  This shows that these 
groupings are robust and are not artifacts of the data analysis methods.  The dendrogram using 
the Jaccard distances is presented. Replicates have Jaccard distance measures at the 0.20 level or 
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below. No differences below the 0.20 level on the Jaccard dendrogram are presented since it 
cannot be determined if the differences are due to variability in the assay or actual sample 
differences.  
 
16S rRNA sequencing of C. botulinum samples. 
Representatives of the various BoNT producing Clostridium strains were selected to 
sequence the 16S rRNA.    The primers 1492R (5’-GGTTACCTTGTTACGACTT-3’) and 27F 
(5’-AGAGTTTGATCMTGGCTCAG-3’) were used to PCR amplify about 1400 bases of the 
1.5kb gene.  The purified PCR template was then sequenced using these primers and internal 
primers 533Fb (5’-GCCAGCAGCNGCGGTAA-3’), 940Fb (5’-CGGGGGYCCGCACAAGC-
3’) and 910Rb (5’-GCCCCCGTCAATTYHTTTGAG-3’).  The 16S rRNA phylogenetic tree was 
created from an alignment of 16S rRNA gene sequences, some of which were new to this study 
and the others of which were obtained from GenBank entries of previously sequenced genes.  It 
should be noted that Clostridium genomes each contain more than one copy or allele of the 16S 
rRNA gene.  After multiple sequence alignment with MUSCLE 
(http://www.drive5.com/muscle/), columns in the alignment in which more than 80% of the 
sequences were represented by a gap character were removed, leaving an alignment of 1329 
bases for phylogenetic analysis.   The phylogenetic tree was calculated with PHYLIP dnadist and 
neighbor programs, using the F84 model of evolution and four sequences from Alkaliphilus 
genus (GenBank entries AY554415, AB037677, AF467248 and AJ630291) to serve as the 
outgroup to the Clostridium genus sequences.  The resulting tree was rendered with treetool 
(http://packages.debian.org/unstable/science/TreeTool/) and the outgroup removed to make the 
final figure. 
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BoNT gene Polymerase Chain Reaction (PCR) amplification and sequencing. 
Overlapping primer pairs covering the coding sequence of the different BoNT genes were 
designed for PCR amplification using available GenBank sequences.  Internal DNA oligomers 
were also designed within each amplicon to provide confirming sequence data in both directions.  
These PCR and sequencing primers for each of the neurotoxin gene fragments are listed in Table 
2. Initial PCR contained 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl2, 0.001% 
(wt/vol) gelatin, 0.2 mM each dNTP, 20 pmol of each primer, 2.5U of Amplitaq DNA 
polymerase (PerkinElmer, Inc., Boston MA) and approximately 1 ng template DNA in 100 µl 
total reaction volume.  Template DNA was initially denatured by heating at 94°C for 2 min.  
This was followed by 35 cycles of denaturation at 94°C for 1 min, annealing at 55°C for 1 min 
and primer extension at 72°C for 1 min.  Incubation for 5 min at 72°C followed to complete 
extension. PCR amplicons were analyzed by electrophoresis through a 3.0% agarose gel 
dissolved in a solution containing 10 mM Tris borate (pH 8.3) and 1 mM EDTA  for 1 hour at 
80V. Gels were stained for 20 min with a solution containing 1 µg of ethidium bromide/ml, de-
stained in distilled water, then visualized and photographed under UV light.  PCR amplicons 
were purified using a Qiagen PCR Purification Kit (Qiagen Inc., Valencia, CA) then sequenced 
using ABI dye terminator 3.1 chemistry on an ABI 3730 instrument.   
 
DNA alignments were created with a combination of Sequencer software 
(http://www.genecodes.com/) PAUP (http://paup.csit.fsu.edu/),  MUSCLE  
(http://www.drive5.com/muscle/), CLUSTAL-W (http://www.ebi.ac.uk/clustalw/) and hand 
editing with BioEdit (http://www.mbio.ncsu.edu/BioEdit/bioedit.html) software and were 
page 13 
gapstripped and then analyzed using PHYLIP 
(http://evolution.genetics.washington.edu/phylip.html) with dnadist with the F84 model of 
evolution and a transition to transversion ratio of 2.0 (default) and neighbor joining algorithms.  
Phylogenetic trees were rendered with treetool  
(http://packages.debian.org/unstable/science/TreeTool/).  Intra- and inter- serotype BoNT gene 
recombination was explored with SimPlot (http://sray.med.som.jhmi.edu/SCRoftware/simplot/), 
and BioEdit.   The Simplot analysis in Figure 4 is a comparison of different  BoNT sequences 
and the BoNT/A2 sequence from GenBank accession number X73423.  It was generated with a 
sliding window of 200 bp and the percent similarity between  the two sequences  plotted at the 
center of the window.  The window was moved 20 bp between each point.  
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Results 
The Clostridium strains used in this study encompass strains collected by various 
researchers over many years. Table 1 lists the strains used in this study and describes  the strain 
identification number from the original researcher or institution if known.  The collection of the 
174 strains included: 59 BoNT/A, 56 BoNT/B, 19 BoNT/C, 6 BoNT/D, 21 BoNT/E, 6 BoNT/F 
and 7 BoNT/G strains and included five bivalent strains (Af695, Bf698, Bf258, Ba207, Ab149).   
For the purposes of the above classification, bivalent strains were classified based on the 
predominant toxin produced.  All strains were tested to confirm that they produced toxin, either 
by ELISA and/or by mouse neutralization assay. The collection contains strains from diverse 
geographic locations and from various sources including specimens from food, adults, infants, 
animals, birds, soil and marine sediments.  
 
16S rRNA Analysis 
Comparative analysis of the nucleotide sequences from the conserved 16S rRNA gene 
using a subset of 109 strains representing the various serotypes in this collection and those from 
other Clostridium species illustrates that the genetic distances between the toxin-producing 
groups are typical of the distances between other species within this genus.  Figure 1 illustrates 
that the toxin producing Clostridia are comprised of the four previously characterized distinct 
phylogenetic clusters, which would logically be defined as species within the Clostridium genus. 
These results confirm and extend the earlier work of many others (7, 22, 23, 40).  The majority 
of the strains in this collection are tightly clustered with16S profiles that are identical to or nearly 
identical to many sequences that have previously been designated as belonging to the proteolytic 
Group I C. botulinum strains that house all of the A, and most of the B and F neurotoxin genes 
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(23).  The remaining strains form phylogenetically distant species clusters that define the 
remaining physiological Groups II, III and IV (22).  The Group II strains include all of the 
neurotoxin E strains, nonproteolytic B strains, and nonproteolytic F strains, and are most closely 
related to species C. beijerinckii and C. butyricum.  Group  III (highly related to C. novyi) encode 
BoNT/C, D, C/D recombinant and D/C recombinant serotypes encoded by toxin operons on a 
bacteriophage.  The 16S sequences of Group IV strains are nearly identical to those of C. 
subterminale and C. argentinense and belong to BoNT serotype G that is encoded by a plasmid.    
 
AFLP Analysis 
The tree generated by AFLP analysis of the Clostridium DNAs is shown in Figure 2. The 
large branching patterns within this tree further resolve the tree obtained with the 16S rRNA 
gene.  The AFLP tree clearly agrees with all other methods for classifying C. botulinum strains, 
including both genetic sequence analysis and the characterization of physiological differences 
used in classical bacteriology.  These physiological differences have historically been used to 
categorize the C. botulinum into Groups I-IV. The AFLP tree shows a large separation between 
the proteolytic (Group 1) and nonproteolytic strains (Groups II, III, and IV) and forms distinct 
branches representing Groups I-IV separated by distances greater than 0.75.  In general, the 
AFLP tree also groups the strains by toxin serotype; i.e., most of those strains producing either 
BoNT/C or BoNT/D, BoNT/E, proteolytic BoNT/F and BoNT/G cluster by toxin serotype within 
distinct branches.  However, the strains representing the different BoNT/A and B subtypes show 
more diversity and are not clearly differentiated using AFLP analysis.  Interestingly, four of the 
five bivalent strains included in this study (Bf698, Bf258, Ba207, and Ab149) also appear as a 
cluster, most closely related to one of the BoNT/B clusters.  Each of these strains produces a 
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unique BoNT/B, termed bivalent BoNT/B (see below) (36).   
 
The Group I BoNT/A strains are found within four AFLP clusters which generally 
contain just one toxin serotype or a single combination of two serotypes.  One branch contains 
most of the BoNT/A producing strains examined (37/59).  These strains produce BoNT/A1 and 
include the ATCC type strain 25763 (A146) and the BoNT/A Hall 174 strain (A143) sequenced 
by the Sanger Institute (http://www.sanger.ac.uk/projects/C_botulinum/).  Of the 37 BoNT/A1 
strains, 29 form a monophyletic cluster by analysis of both the BoNT gene sequence and AFLP 
data and suggest a common clonal derivation of this cluster even though these strains are from 
various geographic locations and sources. Another cluster within the A1 subtype includes 16 
A1(B) strains described as having an A1 subtype with a silent B neurotoxin gene.  Six other 
BoNT/A producing strains in three different clusters are as closely related to BoNT/B producing 
strains as to the other BoNT/A producing strains.  These three distantly related clusters include: 
1) a group of three of the four BoNT/A2 strains (Af695, A693 and A694); 2) a separate cluster 
containing the bivalent Ab strain (Ab149), a BoNT/A1 producing strain (A384) and three 
BoNT/B producing strains; and 3) the A254 strain, also known as Loch Maree.  This strain, from 
a 1922 botulism incident in Scotland (30), was found to produce a unique and not previously 
sequenced BoNT/A which we have designated BoNT/A3 (see below).  In addition, the BoNT/A 
produced by the bivalent strain Ba207 was also not previously described.  We have termed this 
toxin BoNT/A4 (see below). 
 
The AFLP analysis subdivides the Group 1 proteolytic BoNT/B strains into smaller 
clusters which include the serologically distinct BoNT/B1 and BoNT/B2 producing strains (28), 
page 17 
and four bivalent BoNT/B producing strains (Ba207, A149, Bf698, and Bf258) all of which 
produce bivalent BoNT/B toxins.  The most common BoNT/B subtype represented here is the 
BoNT/B2 subtype.  The BoNT/B1 strains are more likely to be of US origin and associated with 
food borne cases due to improperly processed vegetables, where the BoNT/B2 strains are mostly 
from Europe and associated with animal cases or meat.  It is interesting that the original 
BoNT/B2 strain was isolated from a case of infant botulism in Japan, and two recent published 
BoNT/B sequences from soil from Korea (DQ417353 and DQ417354) are also from BoNT/B2 
strains. The BoNT/A2 (Ab149) and BoNT/A3 (A254) subtype strains and proteolytic BoNT/F 
strains cluster in separate branches within the BoNT/B strains.   The five proteolytic BoNT/F 
strains cluster together and are distinct from the other BoNT/B strains.  These branches reveal 
genetic similarities of proteolytic BoNT/B strains with both BoNT/A subtypes and proteolytic 
BoNT/F producing strains, and support the Group I designation for all these strains. The close 
relationship among the BoNT/B and BoNT/F producing strains is also observed in the Group II 
area of the AFLP tree where three  nonproteolytic BoNT/B (B160, B257, B697) producing 
strains cluster and are most closely related to a nonproteolytic BoNT/F producing strain (F550).  
 
In addition, four bivalent strains, Ab (Ab149), Ba (Ba207), and Bf (Bf698 and Bf258) 
included in this study cluster together at the 0.2 level in this area of the AFLP tree.  The genetic 
backgrounds of these four strains cannot be differentiated by AFLP, and their 16S rRNA genes 
were found to be greater than 99.93% identical to one another.  By comparison, A150 and Bf258 
separated by AFLP clustering, were 99.78% identical to each other in 16S rRNA sequence 
comparisons.  These bivalent strains with similar genetic backgrounds each contain combinations 
of the different toxin genes BoNT/A, B and F expressed at different levels.  This appears to 
page 18 
indicate very recent horizontal transfer of these toxin genes into the same bacterial lineage.   
Interestingly, they all appear to be from infant cases of botulism from different geographic 
locations: Sweden, Texas, New Mexico, and Utah. 
 
Group II C. botulinum BoNT/E producing strains, which are usually associated with fish 
and other marine mammals, appear within their own branch of the AFLP tree. The 21 BoNT/E 
producing strains include samples from salmon, whale and soil from the Olympian forest. The 
placement of these Group II BoNT/E strains in a distinct branch of the AFLP tree reflects the 
genetic background of these strains that have evolved to include different hosts and 
environmental  habitats occupied by this serotype. The only C. butyricum strain (E543) 
containing a BoNT/E gene in this study is distant to these other 20 C. botulinum strains and is 
from an infant botulism case in Italy (31).  A small branch within the BoNT/E producing strains 
includes three isolates (E213, E538 and E542) whose differences are below the replicate 
variability in this AFLP analysis. These three isolates received from two different research 
collections (USAMRIID and VPI) of the “beluga” strain were intentionally included in these 
experiments.  These beluga isolates are indistinguishable and add confidence to the results 
obtained using strains collected by different researchers over many years. 
 
Most of the Group III BoNT/C(17/19) and BoNT/D (6/6) serotypes form a distinct 
branch of the AFLP tree. These Group III strains form several clusters containing BoNT/C 
strains or combinations of BoNT/C and D serotypes that are not distinguishable by this method.  
One cluster contains eight BoNT/C strains (C167, C174, C210, C522, C523, C530, C532, C659), 
seven of which are from Western Europe.  These strains are linked to disease in mammals, and 
page 19 
they are either proven to be or thought to be type C strains. Another cluster of five strains, shown 
to be C/D strains, can be mapped to marine or fresh water sediments.  Three of the strains (C525, 
C526, C527) are from marine sediments in the US.  Strain C209, which differs slightly, is from 
Japan.  Other Group III strains are from the US (C529), Japan (D701), South America (C700) 
and Africa (C524, C699, D535).  Two of these isolates, C523 and C650, were identical strains 
that were blindly included in this study and the results show that these two strains cluster at the 
0.2 level by AFLP analysis. A distant branch contains a BoNT C strain (C531) and a BoNT/C/D 
strain (C528) that shows these strains to be most similar to the BoNT/G serotypes.  
 
The last cluster includes the seven BoNT/G strains in the AFLP tree.  This plasmid 
encoded toxin gene was first identified from soil in Argentina (16).  It is not clear if one of the 
strains in this study is from the Argentinian soil, however five strains are from human autopsy 
specimens from Switzerland (38, 39). Four of the five autopsy specimens cluster together, 
however the fifth (G193) is closer to G190 of unknown origin than to the others.  
 
The results of the AFLP analysis supports previous AFLP analysis that showed that this 
technique could differentiate Group I and II C. botulinum strains (26).  The current work extends 
those findings to include strains representative of Group III and IV.  This analysis illustrates the 
relationship of the different genetic backgrounds in the Clostridia that house these neurotoxin 
genes. 
 
Sequencing and analysis of BoNT genes 
To understand how conserved the sequences of the different BoNT genes are within C. 
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botulinum strains of a given serotype, the full length coding sequence of each BoNT/A, B and E 
gene was amplified in overlapping segments by PCR then sequenced. Comparisons of the 
neurotoxin sequences generated from the 60 BoNT/A genes sequenced here, as well as six 
previously published BoNT/A genes, shows that four distinct groups of BoNT/A sequences were 
identified (Figure 3). Most of the BoNT/A producing strains in this study (54/60) show little 
sequence variation in the BoNT/A gene and are of the previously reported BoNT/A1 subtype 
(10, 47).  Within this subtype, 37 of the strains share the identical sequence and differ from 16 of 
the remaining 17 strains in this subtype by two nucleotides.  These 16 strains are A1(B) strains 
that contain a silent BoNT/B gene. Sequences were generated from six of the silent BoNT/B 
genes in these A1(B) strains and compared.  All six of the silent BoNT/B sequences were similar 
to GenBank accession AF300467 (27) that generate a truncated protein from a stop codon at 
amino acid 128.  Four of the sequences (A148, A397, A404, A406) were identical to each other 
but differed from AF300467 by two single nucleotide polymorphisms (SNPs). The other two 
sequences (A408, A411) were identical to each other but different from the other four silent 
BoNT/B sequences by a SNP.  The identification of these different silent BoNT/B gene 
sequences shows that there are more differences in clostridial strains than revealed by AFLP 
analysis, 16S rRNA and BoNT/A sequence analysis. There is some geographic correlation 
among these silent BoNT/B strains. Ten of the 16 silent BoNT/B strains were from a US 
collection and seven specifically map to a region stretching from Scottsbluff, Nebraska south 
through eastern Colorado to northeastern New Mexico.  In contrast, none of the 18 BoNT/A1 
strains from a European collection harbored silent BoNT/B genes (personal communication). 
 
Besides the frequently occurring BoNT/A1 gene, three additional BoNT/A genes were 
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identified (Figure 3).  Four strains produced the previously reported BoNT/A2 (29, 46).  
However, two previously unreported BoNT/A genes were also identified.  One of these, termed 
BoNT/A3, was produced by a single strain (A253, also known as Loch Maree) which was 
isolated from a 1922 botulism outbreak in Scotland (30).  An additional BoNT/A gene, 
BoNT/A4, was sequenced from the bivalent strain Ba207.  Nucleotide and amino acid 
comparisons of the toxin genes of the BoNT/A1-A4 subtypes are shown in Table 3.  Nucleotide 
differences range from 3% to 8%, with amino acid differences ranging from 7% to 16%, with the 
most disparate toxin from BoNT/A1 being BoNT/A3.  Given the level of amino acid differences, 
these two new BoNT/A genes almost certainly represent new BoNT/A subtypes.  
 
Recombination analysis indicates that the A2 lineage, represented in Figure 4 by isolate 
BoNT/A2 (Kyoto-F, GenBank accession X73423) is a relatively recent recombinant between the 
BoNT/A1 (A142) and BoNT/A3 (A254) lineages of BoNT/A gene sequences.  The BoNT/A2 
(strain Kyoto-F) sequence is close to 99% identical to BoNT/A1 strain A142 (this paper) over 
positions 1 to 1146, and close to 99% identical to BoNT/A3 strain A254 (this paper) over 
positions 1147 to 3450.  The BoNT/A3 lineage (strain A254) has a region of the BoNT gene 
between bases 745 and 973 that is 74.7% identical to BoNT/A2 (strain Kyoto-F) and also 74.7% 
identical to BoNT/A1 (strain A142) (Figure 4).  This region encoding a portion of the toxin light 
chain is highly divergent.   When this disparate region of BoNT/A3 (strain 254) was compared to 
the GenBank database using BLAST, the closest matches were all Clostridium botulinum type A 
toxin sequences indicating that this sequence is not the result of recombination with any other 
known BoNT sequence, and almost certainly not recombination with another known serotype.  
The fact that the sequences with less than 99% identity to the query do not form parallel lines, 
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but rather have lines which intersect one another, is suggestive of more ancient recombination 
events.  
 
Comparison of the 53 BoNT/B genes sequenced for this work and an additional seven 
previously published BoNT/B genes also showed four, possibly five, distinct groups.  These 
represent the four previously described BoNT/B subtypes, BoNT/B1, BoNT/B2, bivalent 
BoNT/B, and nonproteolytic BoNT/B (Figure 5) (21, 24, 28, 36, 45).  Compared to BoNT/A, 
each subtype had more members, with BoNT/B2 being produced by the largest number of 
strains.  There was also more nucleotide variation within members of each cluster, compared to 
BoNT/A. Nucleotide and amino acid comparisons of the four BoNT/B subtypes are shown in 
Table 3.  Nucleotide differences range from 2%-4%, with amino acid differences ranging from 
4%-6%.  A single BoNT/B (B506) was sequenced that differed from the closest BoNT/B2 strain 
by 33 nucleotides, which represents a 2% difference at the amino acid level.  It is unknown 
whether this represents a new BoNT/B subtype (BoNT/B3), as the subtype delineation indicates 
a difference in immune recognition by monoclonal antibodies. 
 
Comparison of the 21 BoNT/E genes sequenced for this work and an additional 15 
published BoNT/E genes showed five distinct groups (Figure 6).  The predominant group 
contains 17 strains, producing a previously described BoNT/E which we have termed BoNT/E1 
(35).  Two groups contain sequences from only C. butyricum BoNT/E strains.  One of these 
groups contains 11 identical sequences from C. butyricum strains in China isolated from soil and 
several food borne cases of botulism (43).  The other group contains the C. butyricum BoNT/E 
sequences from an infant botulism case in Italy (35).  Toxins in these three groups differ by 3-5% 
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at the amino acid level and most likely represent distinct subtypes (Table 3).  Four of the strains 
(E185, E540, E545, E549) are within one group which produces a previously unidentified 
BoNT/E we have termed BoNT/E3.  Another two strains (E544, E546) also appear to represent a 
unique group of BoNT/E which we have termed BoNT/E2.  Amino acid differences between 
BoNT/E1, E2,  and E3 range from 1-3%.   It in unknown whether this level of difference would 
represent new BoNT/E subtypes, as the subtype delineation indicates a difference in immune 
recognition by monoclonal antibodies. 
 
A comparison of the BoNT nucleotide sequences from these strains and from available 
GenBank sequences representing all of the serotypes is shown in Figure 7.  The tree indicates 
that the seven BoNT genes form three distinct clusters; a large cluster containing the A, E and F 
neurotoxins, a second cluster comprised of the B and G toxins, and a third comprised of the C 
and D toxins. This relationship among the C. botulinum neurotoxin genes is different than the 
results obtained from the 16S rRNA gene and AFLP analysis (compare to Figures 1 and 2). The 
relationships among the group designations (I-IV) is also not maintained (compare to Figure 2), 
and this suggests that the toxin gene has evolved  separately in different genomic backgrounds . 
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Discussion 
More than 170 strains of BoNT producing clostridial strains were analyzed by different 
molecular methods to evaluate the genetic diversity and understand the evolutionary history 
within this species. The 16S rRNA conserved gene sequences illustrate how the different 
serotypes are closely related to other Clostridia species, AFLP analysis is consistent with the 16s 
rRNA data but adds significant resolution to the genomic background that houses the different 
neurotoxin genes, and finally the diversity within and between the seven BoNT serotypes reveal 
a completely different phylogeny within this species that suggests intra and inter species transfer 
of these genes. 
 
The taxonomy of the C. botulinum species has historically been based on the 
identification and/or expression of botulinum toxin genes. Since C. butyricum and C baratii 
strains have been identified that contain BoNT genes (11, 35), the taxonomy of the toxin 
producing Clostridia has become more complex. The tree generated from 16S rRNA gene 
sequence data suggests that the various botulinum neurotoxins that define the species, 
Clostridium botulinum, are actually housed in genomes from four different clostridial species.  
The 16S rRNA tree shows that BoNT/A and BoNT/B and BoNT/F producing strains are closely 
related to each other and evolved from a common ancestor.  However, the genomes for the 
BoNT/C, D, E and G producing strains have 16S profiles that closely align to distant clostridial 
relatives  C. novyi/C. haemolyticum, C. baratii, and C. suberminale/C. argentinense, respectively 
(Figure 1).  These results should not change the basic nomenclature for C. botulinum to avoid 
confusion and because these taxonomic designations are based on strong phenotypic as well as 
genotypic characteristics.  But the presence of related toxin genes in distant relatives of the 
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clostridia, serves as a reminder that horizontal gene transfer has played a significant role in the 
evolution of Clostridium botulinum.   
 
The AFLP analysis of these strains illustrates clustering by group designation and by 
toxin serotype.  The tree divides the strains into clusters which follow the Group I-IV 
designations, which are based on physiological characteristics.  AFLP clearly separates the 
proteolytic and nonproteolytic types and shows the relationship of the genomic backgrounds 
among strains that are usually defined by the expression of a single 3.8 kb BoNT gene into one 
of seven different serotypes.  This AFLP analysis shows a close relationship of BoNT/A1 
subtypes to the A1(B) strains that are distant from the BoNT/A2 and BoNT/A3 subtypes that lie 
within the BoNT/B1 and BoNT/B2 subtypes.  AFLP also shows relationships among the 
proteolytic BoNT/B and BoNT/F isolates that are mirrored in the nonproteolytic BoNT/B and 
BoNT/F branches.  AFLP analysis supports the Group III clustering of BoNT/C and BoNT/D 
serotypes and the clustering of the Group IV BoNT/G strains as distinct from the other serotypes.  
 
Four out of the five bivalent strains in this study cluster together within a branch of the 
AFLP based tree that also contains strain A254, which produces BoNT/A3.  This branch is also 
related to a branch containing three BoNT/A2 producing strains, including the remaining 
bivalent strain, Af695.  These bivalent strains contain BoNT/A, B and F genes and were all 
isolated from infant botulism cases in different geographic locations.  The genomes of these 
isolates cannot be distinguished by AFLP, yet these strains contain various combinations of 
neurotoxin genes.  The sequences of the individual neurotoxin genes show that the BoNT/B gene 
sequence in all of these strains is of the same subtype (not identical sequences) but that the 
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BoNT/A genes differ, representing different subtypes.  Ab149 contains a BoNT/A2 subtype 
sequence but the Ba207 houses a completely new BoNT/A subtype we have termed BoNT/A4.  
These results suggest either that two lineages of a single strain already carrying the BoNT/B 
gene acquired the BoNT/A2 and BoNT/A4 genes horizontally, or that two strains carrying 
BoNT/A2 and BoNT/A4 genes both acquired the same BoNT/B gene horizontally.  Southern 
blotting or genome analysis of toxin gene integration sites would be necessary to distinguish 
between these possibilities.  
 
Four of the five strains producing two serotypes of BoNT (bivalent strains) were isolated 
from infants with botulism.  This high proportion of bivalent strains found in infants might 
reflect sample bias within this collection, but this tendency has been reported by others (4).  Of 
the ten strains isolated from infant, in this study, four are bivalent.  These ten bivalent strains are 
located in different branches of the AFLP tree and include a C. butyricum BoNT/E producing 
strain (E543) from Italy.  Examination of the sequences of the BoNT/A, B and E genes from 
these infant strains shows that the toxin gene frequently represents a unique cluster within the 
serotype.  Within both the BoNT/A and the BoNT/B gene trees, three of the nine clusters in the 
trees contain BoNT produced by strains from infant cases; all of the bivalent strains producing 
BoNT/B form a unique cluster, as does the single strain (E543) producing BoNT/E. It must be 
noted, though, that the infant strains in this collection were deliberately chosen for their unusual 
characteristics, and that a large collection of infant isolates may show higher percentages of the 
more common BoNT/A1 and BoNT/B1 subtypes. 
 
 The neurotoxin gene sequence comparisons of all of the toxin serotypes (A-G) suggests 
page 27 
the BoNT gene has evolved separately in different genomic backgrounds.  The tree indicates that 
the seven BoNT genes form three distinct clusters; a large cluster consisting of the A, E and F 
neurotoxins, a second cluster comprised of the B and G toxins, and a third comprised of the C 
and D toxins.  These relationships are different than the Group I-IV designations supported by 
the 16S rRNA and AFLP analysis.  This discordant phylogeny suggests gene transfer among 
different clostridial species and C. botulinum has contributed to the movement of the BoNT gene 
into various genetic backgrounds. The nucleotide differences within these neurotoxin genes are a 
result of both natural variation and selection pressure.   Recombination events, similar to that 
illustrated in Figure 4, where an A1/A3 recombination created BoNT/A2, can also be found 
within other toxin gene lineages, including many C/D and D/C interserotype recombination 
events which have previously been reported (32).  Several recombination events within the 
NTNH genes of A1, B and F strains have also been noted (12). 
 
The current analysis of 134 BoNT/A, B, and E toxin genes significantly increases our 
understanding of the extent of subtype variability within these three serotypes.  The neurotoxin 
sequences demonstrate that there is more diversity within these toxin serotypes than previously 
known (summarized in ref. (37)).  Two new BoNT/A genes, one new BoNT/B gene, and two 
new BoNT/E genes were identified.  The two new BoNT/A genes clearly represent new BoNT/A 
subtypes, which we have termed BoNT/A3 and BoNT/A4.  Subtypes have historically been 
defined by the differential binding of monoclonal antibodies (14, 29, 37), and the 15% and 11% 
amino acid difference between BoNT/A1, A3, and A4 would certainly result in differential 
binding of some BoNT/A monoclonal antibodies (37).  The toxins encoded by the new BoNT/B 
gene (BoNT/B3) and the new BoNT/E genes (BoNT/E2 and E3) differ from BoNT/B1 and 
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BoNT/E1 by 4%, 1%, and 2% at the amino acid level respectively.  It is not clear whether these 
new toxins represent new toxin subtypes using the historical standard of monoclonal antibody 
binding.  While single amino acid changes can cause loss of antibody binding, whether the 
amino acid differences in these toxins are large enough to result in differential monoclonal 
antibody binding is unknown and would await studies using panels of monoclonal antibodies.  
However, lacking monoclonal antibody studies, subtypes could also be defined based on 
nucleotide, or more appropriately amino acid, differences especially where multiple members are 
identified from different strains.  This would be the case for the BoNT/E2 and E3 genes. 
 
Accurate analyses and understanding of the recombinations between toxin genes of 
different serotypes and subtypes may be more helpful for identifying potential vaccines and 
therapeutic antibodies than relying on phylogenetic trees or overall pairwise sequence distances.  
For example,  BoNT/A2 represents a recombination of the 5’ end of the BoNT/A1 heavy chain 
gene with the 3’ end of the BoNT/A3 gene.  This analysis permits identification of regions of the 
BoNT that could be used to generate antibodies that can cross react with all three subtypes.  
Similarly, knowledge of the recombination site between BoNT/C and D would identify regions 
for generation of antibodies that would cross react with chimeric BoNT/C-D. 
 
In conclusion, the toxins of C. tetani, C. butyricum, and C. baratii are as similar, or more 
similar, to C. botulinum neurotoxins as the various serotypes of BoNT are to each other.  
Historically the expression of these toxins has been used to taxonomically identify these 
Clostridia as C. botulinum. The presence of these toxins in different genetic backgrounds has 
been observed and suggests their movement both within the species and between other species.  
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Most of these bacteria are found throughout the world and yet there is no geographical 
relationship to the genetic diversity.  Environmental niches, geographic distribution and gene 
transfer mechanisms among these spore forming Clostridia must all interact to produce the 
diversity observed in one of the most lethal neurotoxins known.  The BoNTs produced by these 
clostridial species show dramatic sequence differences both within and between serotypes.  
Identifying the extent of these differences is the crucial first step in the development of detection 
devices,  vaccines, and therapeutics. 
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Figure Legends 
Figure 1.  Phylogenetic tree of Clostidium species based on 16S rRNA gene. 
Neighbor-joining tree of 54 sequences from GenBank accessions and 36 sequences 
representative of the strains from this collection, that illustrates the genetic diversity within the 
Clostiridia.  C. botulinum strains cluster into four distinct groups that follow the Group I-IV 
designation historically based on physiological characteristics. These groups are interspersed 
among the 27 other Clostridia species in the tree. The tree was constructed using an alignment of 
16S rRNA sequences which contained 1329 bases after removal of columns containing more 
than 80% gap characters, and includes sequences from bivalent, nonproteolytic and proteolytic 
toxin producing strains. 
 
Figure 2.  AFLP-based tree of 174 C. botulinum strains. 
DNA fragments generated from the restriction enzyme digestion of each of the strain DNAs were 
ligated to linkers and selectively amplified.  Forty DNA fragments generated by AFLP 
experiments were used as a fingerprint to represent each of the strains. If forty fragments did not 
exist, fewer fragments were used as noted in parentheses. The comparison of fingerprints from 
the 174 strains shows a large separation between the proteolytic (Group 1) and nonproteolytic 
strains (Groups II, III, and IV) and distinct branches representing Groups I-IV. The AFLP groups 
are also generally  distinct  toxin serotypes. The distance measure or genetic distance is the 
proportion of fragments that two samples do not have in common. 
 
Figure 3.  Comparison of BoNT/A gene sequences. 
The full length coding region of the BoNT/A gene in 60 strains and 6 GenBank sequences were 
aligned.  Four distinct subtypes are visible. Most strains (54) are of the BoNT/A1 subtype with 
four within the BoNT/A2 subtype.  Two newly identified subtypes BoNT/A3 and BoNT/A4 each 
contain one member- the A254, Loch Maree strain and the bivalent Ba207 strain-which show 
significant sequence variation compared to BoNT/A1 and A2 subtypes. 
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Figure 4.  Similarity plot comparing BoNT subtype sequences to the BoNT/A2 subtype.   
BoNT sequences of the BoNT/A1, A3 and A4 subtypes and BoNT/B1 and Chinese C. butyricum 
BoNT/E were compared to the BoNT sequence of the BoNT/A2 subtype of Kyoto-F GenBank 
accession number X73423.  This plot illustrates that the BoNT/A2 subtype is close to 99% 
identical to the BoNT/A1 subtype (A142) over nucleotide positions 1 to 1146, and close to 99% 
identical to the BoNT/A3 subtype (A254) over positions 1147 to 3450 showing the BoNT/A2 
subtype is a result to a recombination event between BoNT/A1 and BoNT/A3 lineages of gene 
sequences. 
 
Figure 5. Comparison of BoNT/B gene sequences. 
The full length coding regions of the BoNT/B gene in 53 strains and 7 GenBank sequences were 
aligned.  Four distinct clusters that include the BoNT/B1 and BoNT/B2, bivalent (Ab149, 
Ba207,Bf258, Bf698) and nonproteolytic BoNT/B subtypes are visible. Most strains are of the 
BoNT/B2 subtype with 16 of the BoNT/B1 subtype.  Strain B506 is separate from the other 
BoNT/B2 strains and represents newly identified variation in this serotype.  
 
Figure 6. Comparison of BoNT/E gene sequences. 
The full length coding region of the BoNT/E gene in 21 strains and 15 GenBank sequences were 
aligned resulting in five clusters labeled E1-E5. Two clusters contain sequences from C. 
butyricum BoNT/E strains from Italy or China.   The other subtypes include BoNT/E1, E2 and a 
newly identified subtype labeled BoNT/E3 which has four members (E185, E540, E545, E549). 
 
Figure 7.  Comparison of the seven different serotype BoNT gene sequences. 
Neighbor-joining alignment of the nucleotide coding regions of the seven BoNT genes (A 
through G) including the tetanus toxin. The comparison of the BoNT genes shows a different 
relationship of the serotypes than seen by 16S rRNA or AFLP analysis. Nonproteolytic and 
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bivalent strains (Ba207 and Ab149) as well as representatives of the various subtypes are 
included.    
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Table 1.  C. botulinum strains analyzed. 
______________________________________________________________________________________ 
ID   Serotype Strain Information                   ID   Serotype Strain Information                      ID   Serotype Strain 
Information  
____________________________________________________________________________________________________________ 
   
A142       A Schantz 
A143       A ATCC 3502 (Hall 174) 
A144       A ATCC 17862 
A146       A ATCC 25763 
A147       A CDC 1757 
A148       A CDC 1744 
Ab149    Ab CDC 1436 
A150       A Hall  
A254       A      Loch Maree 
A256       A Hall 5675 
A312       A Prevot Ppois 
A384       A CDC 297 
A385       A Prevot P146 
A386       A VPI 7124   
A387       A ATCC 4894 
A388       A CDC 4997 
A389       A ATCC 449 
A391       A Hall 183  
A393       A Hall 3676  
A394       A Hall 3685a 
A395       A Hall 4934Aa 
A396       A Hall 4834 
A397       A Hall 8388A 
A398       A Hall 8857Ab 
A401       A Hall 11481 
A402       A Hall 11569 
A403       A Hall 17544 
A404       A Hall 6581Ae 
A405       A McClung 447 
A406       A McClung 452 
A407       A CDC 2084 
A408       A CDC 7243 
A410       A CDC 8701 
A411       A CDC 2357 
A412       A McClung 465 
A413       A Prevot 792 
A414       A Prevot 910 
A415       A Prevot 969 
A416       A Prevot 62NCA 
A417       A Prevot P179 
A418       A Prevot 878 
A419       A Prevot 62 
A420       A Prevot 865 
A421       A Prevot F18 
A422       A Prevot F16 
A423       A Prevot F57 
A424       A Prevot Dewping 
A425       A Prevot F60 
A427       A Prevot 697B 
A428       A Prevot F5G 
A429       A Prevot 892 
A487       A ATCC 17916 
A503       A McClung 844 
A504       A McClung 450 
A505       A McClung 457 
A674       A ATCC 7948 
A693       A          FRI honey 
A694       A        Kyoto-F  
Af695     Af        strain 84 
  
 
 
  
  
 
 
B152        B NCTC 7273 
B155        B okra 
B159        B ATCC 17843 
B160        B ATCC 17844 
B161        B ATCC 17845 
B162        B 213B  (ATCC 7949) 
B163        B CDC 1656 
B164        B CDC 1828 
B165        B CDC 1758 
B170        B ATCC 17783 
B192        B contaminant in CDC 714 
Ba207      Ba 657 
B257        B Eklund 17B  
Bf258      Bf An436 
B259        B ATCC 51386 
B260        B ATCC 51387 
B305        B Prevot 59 
B306        B Prevot 25 NCASE 
B307        B Prevot 1740 
B308        B Prevot 1504 
B309        B Prevot CM 
B310        B Prevot 594 
B311        B Prevot B 
B313        B Prevot F11 
B426        B Prevot P64 
B488        B VPI 558 
B489        B VPI 560 
B491        B Prevot 1884BA 
B492        B VPI 3,801 
B493        B CA SHD 
B494        B Smith K. Llbke 
B495        B Smith L-590 
B496        B ATCC 8083 
B497        B Hall 80 
B498        B Hall 178 
B499        B Hall 6517(B) 
B500        B Hall 6560 
B501L     B Hall 6707 
B502        B Hall 10,007 
B506        B CDC 795 
B507        B CDC 8188 
B508        B CDC 6242 
B509        B CDC 6291 
B512        B Prevot 1687 
B513        B Prevot 1662 
B514        B Prevot 1490 
B515        B Prevot 1542 
B516        B Prevot 1552 
B517        B Prevot 2345 
B518        B Prevot 1837 
B519        B Prevot B”B” 
B520        B Prevot 1962”B” 
B521        B Prevot PP 
B696        B Eklund 2B 
B697        B 10068 
Bf698      Bf CDC 3281 
 
 
 
 
 
 
 
 
 
 
C167        C Stockholm 
C169        C 2048-Mich 
C173        C ATCC 17849 (nontoxic 
variant) 
C174        C ATCC 17784 
C209        C 003-9 
C210        C 468 
C522        C Prevot 526 
C523        C Copenhagen 41/59-60 
C525        C 6812 
C526        C Smith 6813 
C527        C Smith 6814 
C528        C 6816 
C529        C 9,846C 
C530        C Prevot 571Y 
C531        C Prevot 2233 
C532        C Prevot 2266 
C659        C Copenhagen 41/59-60 
C699        C Brazil 
C700        C South Africa 
   
D175       D 1873 
D177       D Schantz 
D211       D ATCC 11873 
D534       D ATCC 2751 
D535       D M'Bour 
D701       D CB-16 (nontoxic variant) 
   
E182        E ATCC 17852 
E183        E ATCC 17854 
E184        E ATCC 17855 
E185        E Alaska E43 
E213        E Beluga (ATCC 43181) 
E216        E EF4 
E536        E CDC KA-95B 
E537        E Tenno 
E538        E Beluga (ATCC 43181) 
E539        E Hobbs FT18 
E540        E FDA066B  
E541        E L-572 
E542        E Beluga (ATCC 43181) 
E543        E BL5262 (ATCC 43181) 
E544        E CDC 5247 
E545        E CDC 5258 
E546        E  CDC5906 
E547        E Prevot Ped 1 
E548        E Prevot Ped 4 
E549        E Prevot R81-3A 
E675        E Hazen 36208E, (ATCC 
9564) 
   
F187        F CDC 2821 
F188        F Langeland 
F189        F 6/14 
F550        F Eklund202F  
F552        F Wall strain 8-G, (ATCC 
25764) 
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F658        F Langeland  
  
G190       G 5/18/78 
G193       G 2738 
G194       G 1353 
G195       G 2739  
G196       G 2740 
G197       G 2741  
G198       G 2742 
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Table 2.  Primers used for PCR amplification and sequencing of BoNT/A, B and E genes. 
Primer ID            Type                              Sequence                                             Location* 
BoNT A-1F Amp/Seq        TTTATGGTCATTTAAATAATTAATA   35-59            
BoNT A-1R         Amp/Seq       AATGTTCTAAGTTCCTCAAAG    873-893 
BoNT A-1Fs         Seq                GGTGGAAGTACAATAGATACAG     451-472 
BoNT A-1Rs           Seq                TGTATCTATTGTACTTCCACCC          450-471 
BoNT A-2F       Amp/Seq          AGATCCAGCAGTAACATTAGC               741-761 
BoNT A-2R          Amp/Seq         TCCCAATTATTAACTTTGATACATA      1454-1478 
BoNT A-2Fs         Seq                 GAGATTTACACAGAGGATAATT             1135-1156 
BoNT A-2Rs           Seq                AATTATCCTCTGTGTAAATCTC                        1135-1156 
BoNT A-3F           Amp/Seq           TGCTATGTGTAAGAGGGATAATA                   1379-1401 
BoNT A-3R           Amp/Seq           ATCCCATTTTTCATTTCTTTTACTT                  2193-2217 
BoNT A-3Fs          Seq                 ATACTATGTTCCATTATCTTCG                        1739-1760 
BoNT A-3Rs          Seq                 CGAAGATAATGGAACATAGTAT                     1739-1760  
BoNT A-4F           Amp/Seq            GCTTTAAGTAAAAGAAATGA                           2188-2207 
BoNT A-4R           Amp/Seq           CCAGATTATTTCACCATAAT                             3032-3051 
BoNT A-4Fs         Seq                  ATCAATGCTCTGTTTCATATT                           2462-2482 
BoNT A-4Rs         Seq                  AATATGAAACAGAGCATTGAT                        2462-2482 
BoNT A-5F        Amp/Seq          TGCTATTGTATATAATAGTATG                       2886-2907 
BoNT A-5R         Amp/Seq            TTGACTTCATTACTACTACTT                           3752-3772 
BoNT A-5Fs         Seq                  TTAGGTAATATTCATGCTAGTAA                    3226-3248 
BoNT A-5Rs          Seq                   TTACTAGCATGAATATTACCTAA                    3226-3248 
BoNT A-6F           Amp/Seq          ATATTGTTAGAAATAATGATCG                      3611-3632 
BoNT A-6R      Amp/Seq            TAGTTTGAGATTAATTACAGTG                       3980-4001 
 
BoNT B-1F        Amp/Seq          CAATATACCTAAAGCTGCACA                             26-46     
BoNT B-1R         Amp/Seq          TACTTTAATGCCATATAATCCA                          807-828          
BoNT B-1Fs         Seq                 CATTGGGTGAAAAGTTATTAGA                         404-425 
BoNT B-1Rs         Seq                TCTAATAACTTTTCACCCAATG                           404-425     
BoNT B-2F         Amp/Seq           CAGAATATGTAAGCGTATTTA                            686-706 
BoNT B-2R         Amp/Seq          ATCAGTAAGTGATTCTGTATTT                         1614-1635 
BoNT B-2Fs          Seq                 TATAGCAGAAAATTATAAAATAAA                 1176-1199        
BoNT B-2Rs          Seq                 TTTATTTTATAATTTTCTGCTATA                      1176-1199          
BoNT B-3F          Amp/Seq          AGGAGCATTTGGCTGTATAT                              1373-1392 
BoNT B-3R        Amp/Seq              AATGCTTGTGCTTGATAATTTA                          2264-2285 
BoNT B-3Fs          Seq                 GGATTATATTAAAACTGCTAAT                         1821-1842 
BoNT B-3Rs         Seq                     ATTAGCAGTTTTAATATAATCC                          1821-1842 
BoNT B-4F        Amp/Seq               ATATGTACGGATTAATAGTAGC                         2180-2201 
BoNT B-4R       Amp/Seq              TTACCCCTAATAGATATTTTCC                           2981-3002 
BoNT B-4Fs         Seq                      AGATGAAAATAAATTATATTTAA                      2526-2548 
BoNT B-4Rs         Seq                    TTAAATATAATTTATTTTCATCT                        2526-2548 
BoNT B-5F      Amp/Seq                 TATACAAAATTATATTCATAATGA                   2919-2942 
BoNT B-5R      Amp/Seq                ATCTTCTTTTCTAACTATATCATC                     3568-3591 
BoNT B-5Fs         Seq                  TATAAAATTCAATCATATAGCG                        3319-3340 
BoNT B-5Rs        Seq                  CGCTATATGATTGAATTTTATA                         3319-3340 
BoNT B-6F      Amp/Seq           GAGAAAAATTTATTATAAGAAG                       3521-3542 
BoNT B-6R      Amp/Seq          TAGCTACATCCTTAAACTTAAGAT                   4028-4051 
BoNT B-6Fs        Seq           TAAAAGAATATGATGAACAGCC                      3725-3746 
BoNT B-6Rs         Seq           GGCTGTTCATCATATTCTTTTA                          3725-3746 
 
BoNT E-1F          Amp/Seq         GTGATCTTAATCATGATATACC                  145-166 
BoNT E-1R          Amp/Seq          TTAATGTAAGAGCAGGATCT                       839-858 
BoNT E-1Fs           Seq               TAGTCACAAAAATATTTAATAGAA            484-507       
BoNT E-1Rs           Seq               TTCTATTAAATATTTTTGTGACTA               484-507 
BoNT E-2F           Amp/Seq         TGGATCAATAGCTATAGTAACA                 761-782 
BoNT E-2R         Amp/Seq          GGTGCTGATTCACTATTAAA                       1650-1669 
BoNT E-2Fs           Seq                 TTATACAGCTTTACGGAATTTG                  1218-1239                     
BoNT E-2Rs          Seq                CAAATTCCGTAAAGCTGTATAA                 1218-1239 
BoNT E-3F         Amp/Seq         TGGCTTCCGAGAATAGTT                            1537-1554 
BoNT E-3R         Amp/Seq          ATTCATTGCTATAGAAACCTTT                  2474-2495 
BoNT E-3Fs          Seq                GTACTGTTGATAAAATTGCAGA                 1999-2020            
BoNT E-3Rs         Seq                 TCTGCAATTTTATCAACAGTAC                  1999-2020         
BoNT E-4F        Amp/Seq           GAACAAATGTATCAAGCTTT                       2331-2350 
BoNT E-4R        Amp/Seq          TGTCACTAACATGAATATTACC                  3288-3309 
BoNT E-4Fs         Seq                ACTTCAGGATATGATTCAAATA                  2820-2841 
BoNT E-4Rs          Seq                TATTTGAATCATATCCTGAAGT                   2820-2841 
BoNT E-5F        Amp/Seq          TGATTATATAAATAAGTGGATT                  3179-3200 
BoNT E-5R        Amp/Seq           TGGAATTTATGACTTTAGCC                        4001-4020 
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BoNT E-5Fs          Seq                  GCTAATAGATTATATAGTGGAA                 3579-3600 
BoNT E-5Rs         Seq                  TTCCACTATATAATCTATTAGC                   3579-3600 
*Location of primer sequence of BoNT A within GenBank accession   X73423  
  Location of primer sequence of BoNT B within GenBank accession   X71343 
  Location of primer sequence of BoNT E within GenBank accession  X62683 
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Table 3. Nucleotide and amino acid identities in strains representing BoNT/A, B and E 
subtypes1.  The coding sequence for a representative of each different subtype of BoN/A, B and 
E was compared to determine overall homology at both the nucleic acid and amino acid level; 
npB (nonproteolytic B), bvB  (bivalent B), It butyr (Italian C.  butyricum strain BL5262), Ch 
butyr (Chinese C. butyricum strain LCL155). 
       
BoNT/A A1 
(A150 Hall) 
A2 
(Ab149 CDC 
1436) 
A3 
(A254 Loch 
Maree) 
A4 
(Ba207 strain 
657) 
 
A1 ----- 95 %/90 % 92 %/85 % 94 %/89 %  
A2  ----- 97 %/93 % 94 %/88 %  
A3   ----- 92 %/84 %  
A4    -----  
BoNT/B B1 
(B155 okra) 
B2 
(B162 213B) 
B3 
(B506 CDC 795) 
NpB2 
(B257 Eklund 
17B) 
BvB3 
(Ba207 strain 
657) 
B1 ----- 98 %/96 % 98 %/96 % 96 %/93 % 98 %/96 % 
B2  ----- 99 %/98 % 96 %/94 % 97 %/95 % 
B3   ----- 96 %/94 % 98 %/96 % 
npB2    ----- 96 %/93 % 
bvB3     ----- 
BoNT/E E1 
(E213Beluga) 
E2 
(E544 CDC5247) 
E3 
(E185 AlaskaE43) 
E It butyr4 
(E543 BL5262) 
E Ch butyr5 
(LCL155) 
E1 ----- 99 %/99 % 99 %/98 % 98 %/97 % 98 %/97 % 
E2  ----- 99 %/97 % 98 %/96 % 98 %/96 % 
E3   ----- 98 %/96 % 98 %/95 % 
E It butyr    ----- 97 %/95 % 
E Ch 
butyr 
    ----- 
 
1Identity at DNA level / identity at amino acid level 
 
2npB (nonproteolytic B)  
3bvB  (bivalent B) 
4It butyr (Italian C. butyricum strain BL5262)  
5Ch butyr (Chinese C. butyricum strain LCL155). 
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